Navigation Links
Acacia Pharma Raises £15 Million ($23.5 Million) to Advance Clinical Development of Lead Products for Supportive Care
Date:9/3/2013

s (http://www.fidelitybiosciences.com) invests venture capital in biopharmaceutical, medical technology, healthcare information technology and healthcare service companies. The firm is a subsidiary of FMR LLC, the parent company of Fidelity Investments, one of the world's leading providers of financial services. For more than 40 years, Fidelity has been a significant presence in the venture capital and private equity industry. For more information, visit the website above.

About Novo A/S

Novo (http://www.novo.dk).is the holding company of the Novo Group, and is wholly owned by the Novo Nordisk Foundation. It was established in 1999 to manage the assets of the foundation and actively make investments on its behalf. Novo Ventures focuses on life sciences venture capital, and is active in both Europe and North America. The firm has four partners in Copenhagen, one in London and four in San Francisco. With an evergreen structure, it annually invests approximately $150 million in venture capital into private and public life sciences companies.

About Lundbeckfond Ventures

Lundbeckfond Ventures (http://www.lundbeckfondventures.dk) is an evergreen life science venture fund investing in companies in Europe and in the US. It is financially driven and invests primarily in drug development, as well as in medtech. Lundbeckfond Ventures is part of the asset management subsidiary of the Lundbeck Foundation which in addition to substantial financial assets has controlling ownerships in H. Lundbeck A/S, ALK-Abelló A/S and Falk A/S.

About Gilde Healthcare 
Gilde Healthcare (Utrecht, The Netherlands and Cam
'/>"/>

SOURCE Acacia Pharma
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. 6th BSMA Annual Executive Summit to Address the Supply Chain Challenges and Solutions of Biopharma
2. Before the Bell Scans: Hologic Inc., St. Jude Medical Inc., ResMed Inc., and Navidea Biopharmaceuticals Inc.
3. BIOPHARMA Executives Summit, 6th BSMA Annual Conference: Look Who Is Confirmed to Speak
4. EnduRx Pharmaceuticals to Present at 2013 Rocky Mountain Life Science Investor and Partnering Conference
5. Rational Design of Modified Release Dosage Forms: From Pharmacokinetic Targets Through Technology Selection, new life science webinar hosted by Xtalks
6. New Book Provides Industry Guidance for Major Pharmaceutical Firms
7. HealthCare, Technology Briefing: Market Movers for the Week - Technologies-Scan Corp, GNC, Galena Biopharma, Immunomedics, Amarin
8. Pharma Contract Manufacturing, Research & Packaging Market a New Report Available at ReportsnReports.com
9. Cambridge Semantics to Present on Smart Data and Competitive Intelligence Informatics at 2013 Pharma CI Conference & Exposition
10. Pharmaceutical and Food Product Safety Made Easier with the Environmental Wireless Validation System by Deadline Solutions, Inc
11. FDAs Lawrence Yu to Participate in Live Video Chat on Question-Based Review (QbR) for Generics on CPhI Pharma Evolution
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Dec. 23, 2014 China Biologic Products, ... a leading fully integrated plasma-based biopharmaceutical company in ... its majority-owned subsidiary, Shandong Taibang Biological Products Co. ... from the China Food and Drug Administration (the ... As previously disclosed in the Company,s public filings, ...
(Date:12/24/2014)... Fla. , Dec. 23, 2014  Rock Creek ... that it has filed a Clinical Trial Application (CTA) ... Healthcare products Regulatory Agency (MHRA) seeking regulatory approval to ... lead molecule, Anatabine Citrate. Contingent on the ... conduct a Phase I trial to assess the safety, ...
(Date:12/22/2014)... /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V: ... the development of autologous cell therapies, announced today the ... Calgary in conjunction with co-authors from Kyoto University and ... company,s ongoing clinical research using dermal sheath cup (DSC) ... The paper entitled " Hair Follicle Dermal Stem ...
(Date:12/22/2014)... The American Journal of Hematology/Oncology, ... reviews and editorials addressing developments and pathways related ... a provocative article exploring the role of follicle-stimulating ... treatment of prostate cancer. , The article ... possibility that there could be a connection to ...
Breaking Biology Technology:China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4
... Biosciences,Corporation (Nasdaq: MATK ) today announced that ... Wilmington, Delaware, has ruled on various,post-trial motions and ... the defendants in the patent infringement suit brought ... Nutrition Specialties &,Food Ingredients GmbH. The suit involves ...
... Nov. 1 ThermoGenesis,Corp. (Nasdaq: KOOL ), a ... store, and administer therapeutic doses of,adult stem cells for ... financial results for the fiscal first quarter ended September,30, ... Call and Webcast Management will host a conference ...
... technical feasibility of ... ... TSX symbol: SBS, CALGARY, Nov. 1 /PRNewswire-FirstCall/ - ... for metabolic and cardiovascular diseases, today announced its,2007 third quarter operational ...
Cached Biology Technology:Martek to Obtain Permanent Injunction Against Lonza in U.S. Patent Infringement Suit; Jury Verdict on Infringement of Two of Three Patents Upheld by Judge 2Martek to Obtain Permanent Injunction Against Lonza in U.S. Patent Infringement Suit; Jury Verdict on Infringement of Two of Three Patents Upheld by Judge 3ThermoGenesis Corp. to Announce First Quarter Fiscal 2008 Results on November 8, 2007 2ThermoGenesis Corp. to Announce First Quarter Fiscal 2008 Results on November 8, 2007 3SemBioSys announces 2007 third quarter results 2SemBioSys announces 2007 third quarter results 3SemBioSys announces 2007 third quarter results 4SemBioSys announces 2007 third quarter results 5SemBioSys announces 2007 third quarter results 6SemBioSys announces 2007 third quarter results 7SemBioSys announces 2007 third quarter results 8SemBioSys announces 2007 third quarter results 9SemBioSys announces 2007 third quarter results 10SemBioSys announces 2007 third quarter results 11SemBioSys announces 2007 third quarter results 12
(Date:12/19/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/8kmfcn/iphone_5s ) ... 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire ... http://photos.prnewswire.com/prnh/20130307/600769 ... 2012, Apple introduced the fingerprint reading feature with ... device of Apple incorporating such a feature, called ...
(Date:12/19/2014)... , Dec. 18, 2014   LaunchKey , the ... the post-password and Internet of Things era, today announced ... The venture round was led by Metamorphic Ventures with ... Venture Partners, VegasTechFund, and others.  LaunchKey has raised $4 ... to expand its team and bring LaunchKey to market ...
(Date:12/17/2014)... Dec. 15, 2014  HITLAB SM announced ... (GCP) audit to confirm its adherence to current ... accomplishment enables HITLAB to conduct regulated smart device ... principles for patient safety and research quality. ... access, quality, and delivery with innovative technology," said ...
Breaking Biology News(10 mins):iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2
... high blood pressure drugs may be useful in preventing and ... people with diabetes. The study, the largest to date on ... prevent or treat the sight-threatening disease, they say. The findings ... monthly publication. Edward Feener and colleagues point out ...
... Pneumonia A group led by Dr. James ... Human Infectious Diseases Research of The Methodist Hospital Research ... Paton-Valentine leukocidin (PVL) does not affect methicillin-resistant Staphlococcus ... can be found in the March 2010 issue of ...
... -- Oak Ridge National Laboratory researchers will lead projects ... processor hours of computing time on supercomputers located at ... awards were made through the U.S. Department of Energy ... Experiment (INCITE) program. This year, the INCITE program will ...
Cached Biology News:Tips from the American Journal of Pathology 2Tips from the American Journal of Pathology 3Tips from the American Journal of Pathology 4Tips from the American Journal of Pathology 52010 DOE INCITE projects allocated at ORNL 22010 DOE INCITE projects allocated at ORNL 32010 DOE INCITE projects allocated at ORNL 4
Guanine nucleotide-binding protein G(k), alpha subunit...
ICAD Purified Anti-Mouse clone Polyclonal, Isotype Rabbit Ig, 200 µl Consult technical datasheet for details....
Indoleamine 2,3-dioxygenase [IDO]...
Recognizes the 41 and 43 kDa G-proteins present in liver plasma membranes and Gq/11alpha expressed in the Sf9 insect cell expression system. Negative for recombinant G(I)alpha subtypes....
Biology Products: